Scientific Materials
Assessing Interaction Recovery of Predicted Protein-ligand Poses
Improving Generalisability of 3D Binding Affinity Models in Low Data Regimes
MolE: a foundation model for molecular graphs using disentangled attention
_VSCO-min.jpg)
In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia
-min.jpg)
Combining Next-generation BTK and MALT1 Inhibitors to Enhance Efficacy and Therapeutic Utility in B-cell Malignancies
-min.jpg)
Hands-off Screening With Cells: Automation of a Cellular Biosensor to Facilitate Efficient Hit Compound Screening
Building, Benchmarking, and Exploring Perturbative Maps of Transcriptional and Morphological Data
-min.jpg)
ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia
-min.jpg)
Generative Design Using Active Learning Over Synthon Space
-min.jpg)
New Computational Methods for the Early Characterisation of Drug-induced Liver Toxicity
REC-3964, a First-in-Class Molecule for the Prevention of Recurrent Clostridioides difficile Infection
Masked Autoencoders for Microscopy are Scalable Learners of Cellular Biology
High-Resolution Genome-Wide Mapping of Chromosome-Arm-Scale Truncations Induced by CRISPR–Cas9 Editing
-min_VSCO-min.jpg)
Risk Mitigation in Target Assessment: Chemical and Structural Approaches to Chemical Tractability
.png)
Phenomics-Enabled Discovery and Optimization of Small Molecule RBM39 Degraders as Alternative to CDK12 Targeting in High-Grade Serious Ovarian Cancer (HGSOC)
Clinical Pharmacology and Tolerability of REC-994, A Redox-Cycling Nitroxide Compound, in Randomized Phase 1 Dose-Finding Studies
Bridging AI-driven Design and Lab Automation for Accelerated Drug Discovery
-min.jpg)
Characterisation of EXS73565, a Potent and Selective MALT1 Inhibitor with Low Drug-drug Interaction Risk and Potential in Lymphoma
-min.jpg)
Determining Anti-cancer Efficacy of a Reversible LSD1 Inhibitor, EXS74539, in Primary AML Tissues with Limited Thrombocytopenic Effects
.png)
Masked Autoencoders Are Scalable Learners of Cellular Morphology
-min.jpg)
Automated Design of Kinase Inhibitors Using AlphaFold2 Models
Automating Structure-based Design: Integrating Fragment Hotspot Maps in Drug Discovery Pipelines at Scale
Discovery of a Novel DCAF1 Ligand Using a Drug–Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets
Computer-aided Biology (CAB): DoE Solutions
-min.jpg)
Improving Assay Optimisation and Pharmacological Sensitivity of a Nuclease by Employing a Computer-aided Biology Approach
TUPELO Trial: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Subjects With Familial Adenomatous Polyposis (FAP): Study Design
-min.jpg)
Characterizing Antitumor Responses to EXS74539, a Novel, Reversible LSD1 Inhibitor with Potential in Small-cell Lung Cancer
A Phenomics Platform Combining Imaging and Artificial Intelligence for Rapid Validation and Advancement of Novel Oncology Targets
Testing the Limits of SMILES-based De Novo Molecular Generation with Curriculum and Deep Reinforcement Learning
.jpg)
Biological Cartography: Building and Benchmarking Representations of Life
Multi-Objective GFlowNets
MolE: A Molecular Foundation Model for Drug Discovery
-min.jpg)
Defining Activity and Patient Selection of a Novel CDK7 Inhibitor, GTAEXS617, Through AI-supported Primary Cancer Tissue Profiling
Obtaining Cellular Morphological Embeddings Across Experimental Batches
.jpg)
POPLAR-NF2: A Parallel-Group, Two-Staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2-Mutated Meningiomas
-min.jpg)
AI-driven Discovery and Profiling of GTAEXS617, a Selective and Highly Potent Inhibitor of CDK7
Identification and Optimization of Novel Small Molecule Modulators of Immune Checkpoint Resistance with a Unified Representation Space for Genomic and Chemical Perturbations
Fragment Hotspot Mapping to Identify Selectivity-determining Regions Between Related Proteins
Mapping Biology with a Unified Representation Space for Genomic and Chemical Perturbations to Enable Accelerated Drug Discovery
WILDS: A Benchmark of in-the-Wild Distribution Shifts
Functional Immune Mapping with Deep-Learning Enabled Phenomics Applied to Immunomodulatory and COVID-19 Drug Discovery
Identification of Potential Treatments for COVID-19 through Artificial Intelligence-Enabled Phenomic Analysis of Human Cells Infected with SARS-CoV-2
Cell Painting, a High-Content Image-Based Assay for Morphological Profiling Using Multiplexed Fluorescent Dyes
A New Phenotypic Lexicon for Accelerated Translation
Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation
Scientific Materials
Assessing Interaction Recovery of Predicted Protein-ligand Poses
Dec 15, 2024
|
NeurIPS 2024 Workshops
|
Platform
Improving Generalisability of 3D Binding Affinity Models in Low Data Regimes
Dec 15, 2024
|
NeurIPS 2024 Workshops
|
Platform
MolE: a foundation model for molecular graphs using disentangled attention
Nov 12, 2024
|
Nature Communications
|
Platform
In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia
Oct 24, 2024
|
ENA 2024
|
Pipeline
Combining Next-generation BTK and MALT1 Inhibitors to Enhance Efficacy and Therapeutic Utility in B-cell Malignancies
Oct 24, 2024
|
ENA 2024
|
Pipeline
Hands-off Screening With Cells: Automation of a Cellular Biosensor to Facilitate Efficient Hit Compound Screening
Oct 2, 2024
|
Discovery on Target 2024
|
Platform
Building, Benchmarking, and Exploring Perturbative Maps of Transcriptional and Morphological Data
Oct 1, 2024
|
PLOS Computational Biology
|
Platform
ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia
Sep 29, 2024
|
ASBMR 2024
|
Pipeline
Generative Design Using Active Learning Over Synthon Space
Sep 24, 2024
|
EuroQSAR Symposium 2024
|
Platform
New Computational Methods for the Early Characterisation of Drug-induced Liver Toxicity
Sep 9, 2024
|
EUROTOX 2024
|
Platform
REC-3964, a First-in-Class Molecule for the Prevention of Recurrent Clostridioides difficile Infection
Jun 24, 2024
|
6th Edition of World Congress on Infectious Diseases
|
Pipeline
Masked Autoencoders for Microscopy are Scalable Learners of Cellular Biology
Jun 21, 2024
|
Conference on Computer Vision and Pattern Recognition (CVPR)
|
Platform
High-Resolution Genome-Wide Mapping of Chromosome-Arm-Scale Truncations Induced by CRISPR–Cas9 Editing
May 29, 2024
|
Nature Genetics
|
Platform
Risk Mitigation in Target Assessment: Chemical and Structural Approaches to Chemical Tractability
Apr 29, 2024
|
Target to Patient 2024
|
Platform
Phenomics-Enabled Discovery and Optimization of Small Molecule RBM39 Degraders as Alternative to CDK12 Targeting in High-Grade Serious Ovarian Cancer (HGSOC)
Apr 10, 2024
|
AACR Annual Meeting
|
Platform
Clinical Pharmacology and Tolerability of REC-994, A Redox-Cycling Nitroxide Compound, in Randomized Phase 1 Dose-Finding Studies
Apr 5, 2024
|
Pharmacology Research & Perspectives
|
Pipeline
Bridging AI-driven Design and Lab Automation for Accelerated Drug Discovery
Nov 27, 2023
|
Automated Synthesis Forum 2023
|
Platform
Characterisation of EXS73565, a Potent and Selective MALT1 Inhibitor with Low Drug-drug Interaction Risk and Potential in Lymphoma
Oct 23, 2023
|
ESMO 2023
|
Pipeline
Determining Anti-cancer Efficacy of a Reversible LSD1 Inhibitor, EXS74539, in Primary AML Tissues with Limited Thrombocytopenic Effects
Oct 21, 2023
|
ESMO 2023
|
Pipeline
Masked Autoencoders Are Scalable Learners of Cellular Morphology
Sep 27, 2023
|
arXiv
|
Platform
Automated Design of Kinase Inhibitors Using AlphaFold2 Models
Sep 14, 2023
|
UK-QSAR Autumn Meeting 2023
|
Platform
Automating Structure-based Design: Integrating Fragment Hotspot Maps in Drug Discovery Pipelines at Scale
Jun 24, 2023
|
ISMB/ECCB 2023
|
Platform
Discovery of a Novel DCAF1 Ligand Using a Drug–Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets
Jun 23, 2023
|
Journal of Chemical Information and Modeling
|
Platform
Computer-aided Biology (CAB): DoE Solutions
May 25, 2023
|
SLAS EU 2023
|
Platform
Improving Assay Optimisation and Pharmacological Sensitivity of a Nuclease by Employing a Computer-aided Biology Approach
May 24, 2023
|
SLAS EU 2023
|
Platform
TUPELO Trial: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Subjects With Familial Adenomatous Polyposis (FAP): Study Design
May 6, 2023
|
11th Annual Clinical Cancer Genetics and Genomics Conference
|
Pipeline
Characterizing Antitumor Responses to EXS74539, a Novel, Reversible LSD1 Inhibitor with Potential in Small-cell Lung Cancer
Apr 19, 2023
|
AACR 2023
|
Pipeline
A Phenomics Platform Combining Imaging and Artificial Intelligence for Rapid Validation and Advancement of Novel Oncology Targets
Apr 17, 2023
|
AACR Annual Meeting
|
Platform
Testing the Limits of SMILES-based De Novo Molecular Generation with Curriculum and Deep Reinforcement Learning
Apr 3, 2023
|
Nature Machine Intelligence 2023
|
Platform
Biological Cartography: Building and Benchmarking Representations of Life
Dec 9, 2022
|
Learning Meaningful Representations of Life (LMRL) Workshop at NeurIPS
|
Partnership
Multi-Objective GFlowNets
Dec 2, 2022
|
AI for Accelerated Materials Design (AI4Mat) Workshop at NeurIPS
|
Platform
MolE: A Molecular Foundation Model for Drug Discovery
Nov 8, 2022
|
Learning Meaningful Representations of Life (LMRL) Workshop at NeurIPS
|
Platform
Defining Activity and Patient Selection of a Novel CDK7 Inhibitor, GTAEXS617, Through AI-supported Primary Cancer Tissue Profiling
Oct 26, 2022
|
ENA 2022
|
Pipeline
Obtaining Cellular Morphological Embeddings Across Experimental Batches
Oct 18, 2022
|
CytoData Symposium
|
Platform
POPLAR-NF2: A Parallel-Group, Two-Staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2-Mutated Meningiomas
Jun 19, 2022
|
NF Conference
|
Pipeline
AI-driven Discovery and Profiling of GTAEXS617, a Selective and Highly Potent Inhibitor of CDK7
Apr 13, 2022
|
AACR 2022
|
Pipeline
Identification and Optimization of Novel Small Molecule Modulators of Immune Checkpoint Resistance with a Unified Representation Space for Genomic and Chemical Perturbations
Apr 8, 2022
|
AACR Annual Meeting
|
Platform
Fragment Hotspot Mapping to Identify Selectivity-determining Regions Between Related Proteins
Jan 12, 2022
|
Journal of Chemical Information and Modeling 2022
|
Platform
Mapping Biology with a Unified Representation Space for Genomic and Chemical Perturbations to Enable Accelerated Drug Discovery
Nov 30, 2021
|
NeurIPS Learning Meaningful Representations of Life Workshop
|
Platform
WILDS: A Benchmark of in-the-Wild Distribution Shifts
Jun 30, 2021
|
International Conference on Machine Learning
|
Platform
Functional Immune Mapping with Deep-Learning Enabled Phenomics Applied to Immunomodulatory and COVID-19 Drug Discovery
Aug 20, 2020
|
bioRxiv
|
Platform
Identification of Potential Treatments for COVID-19 through Artificial Intelligence-Enabled Phenomic Analysis of Human Cells Infected with SARS-CoV-2
Apr 23, 2020
|
bioRxiv
|
Platform
Cell Painting, a High-Content Image-Based Assay for Morphological Profiling Using Multiplexed Fluorescent Dyes
Aug 25, 2016
|
Nature Protocols
|
Platform
A New Phenotypic Lexicon for Accelerated Translation
Jan 20, 2015
|
Circulation
|
Platform
Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation
Dec 8, 2014
|
Circulation
|
Pipeline
Open Source Data Sharing
We believe in the benefits of open source and open science, and that by releasing open datasets, we drive value for us and society as a whole. Visit www.rxrx.ai to explore our released datasets.
COVID-19
In 2020, we acted boldly to contribute data to the scientific community in hopes it would be useful in fighting the COVID-19 pandemic. We partnered with a biosafety level 3 facility to infect a variety of human cells with live SARS-CoV-2 virus, and used our platform to investigate the therapeutic potential of a library of approved drugs. We released our findings as an open-source dataset for the scientific community in April of 2020, which can be downloaded here. Following our initial dataset release, we used our platform to model and screen for therapeutics that can treat the most severe forms of COVID-19 that have progressed to acute respiratory distress syndrome (ARDS). We modeled the cytokine storm associated with late-stage COVID-19, treated it with a library of approved drugs, and in August 2020, released the first morphological dataset representing inflammatory effects and potential treatments in the context of COVID-19 ARDS, along with a preprint of our findings.
RxRx Series
We have also released some of the largest open-sourced biological datasets in the world, the RxRx series, under terms that allow for broad academic and non-commercial use. As part of the series, we also released a preprint that demonstrates the capabilities of Recursion’s platform to model complex immune biology and screen for new therapeutics. To explore our released datasets, please visit our website at www.rxrx.ai. Our contribution to a greater understanding of human biology is just as important as the medicines we advance.
Phenom-Beta
We have released the first in a potential series of foundation models for external use (both non-commercial and commercial) hosted on NVIDIA’s BioNeMo platform. We call this model Phenom-Beta. It flexibly processes microscopy images into general-purpose embeddings. In other words, Phenom-Beta can take a series of images and create a meaningful representation of the input image. This enables robust comparison of images, and other data science techniques to decode any biology or chemistry within such images. This allows scientists to systematically relate genetic and chemical perturbations to one another in a high-dimensional space, helping determine critical mechanistic pathways and identify potential targets and drugs. Currently, the model is available through the API and will be available through BioNeMo Beta. Learn more at at www.rxrx.ai.
Want to help us explore the uncharted?
We're working to solve some of the most meaningful problems facing human health today. Come do the most impactful work of your career at a company that prioritizes belonging, collaboration and career development.
